路透2月24日 - 中国生物科技公司先为达生物:
中国生物科技公司先为达生物:将降糖减重药埃诺格鲁肽注射液在中国大陆的独家商业化权益授予辉瑞PFE.N
先为达生物:将有权获得辉瑞支付的最高可达4.95亿美元的付款总额,包括首付款、注册及销售里程碑付款
浏览公告详情,请点击此处
(发稿 徐凯文)
((Kaiwen.Xu@thomsonreuters.com;))
路透2月24日 - 中国生物科技公司先为达生物:
中国生物科技公司先为达生物:将降糖减重药埃诺格鲁肽注射液在中国大陆的独家商业化权益授予辉瑞PFE.N
先为达生物:将有权获得辉瑞支付的最高可达4.95亿美元的付款总额,包括首付款、注册及销售里程碑付款
浏览公告详情,请点击此处
(发稿 徐凯文)
((Kaiwen.Xu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.